Mario Thomas
Président chez Precision Biomonitoring, Inc.
Profil
Dr. Mario Thomas is a Managing Director at Ontario Centres of Excellence, Inc. and Senior Vice President at Ontario Centres of Excellence.
In addition to his current role at Ontario Centres of Excellence, Dr. Thomas is a Managing Director at Ontario Centres of Excellence, Inc and Vice President at Gestion T2C2.
He is on the Board of Directors at DiagnoCure, Inc., Topigen Pharmaceuticals, Inc., and TransPharma Medical Ltd.
Dr. Thomas was previously employed as Vice President by Transfer Technologies Commercialisation Capital, Chairman & Chief Executive Officer by Entomed SA, President & Chief Executive Officer by Terragen Discovery, Inc., Vice President-Business Development by Biochem Pharma, Inc., and a Principal by Johnson & Johnson.
He also served on the board at Biogentis, Inc. and Aurelium BioPharma, Inc.
Dr. Thomas received his doctorate degree from Université Laval.
Postes actifs de Mario Thomas
| Sociétés | Poste | Début |
|---|---|---|
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Directeur/Membre du Conseil | - |
Precision Biomonitoring, Inc.
 Precision Biomonitoring, Inc. Medical/Nursing ServicesHealth Services Precision Biomonitoring, Inc. was founded in 2016 and specializes in providing SARS-CoV-2 test solutions for businesses. The private company is based in Guelph, Canada. The Canadian company's services include both mobile and laboratory RT-qPCR solutions. | Président | - |
Anciens postes connus de Mario Thomas
| Sociétés | Poste | Fin |
|---|---|---|
| 9342-8530 QUÉBEC INC. | Directeur/Membre du Conseil | 26/11/2012 |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private Equity Investor | 31/03/2009 |
| Gestion T2C2/Bio, Inc. | Corporate Officer/Principal | 01/01/2009 |
Biogentis, Inc.
 Biogentis, Inc. Pharmaceuticals: MajorHealth Technology Biogentis, Inc. is a biopharmaceutical company, which designs and develops healthcare solutions in the field of advanced wound care and regenerative medicines. The company provides three technology platforms: Dermalink, a fibronectin-based product for chronic wound healing, CyanoStrip, a wound closure system and a self-assembly tissue engineering technology. It is located in Montréal, Canada | Directeur/Membre du Conseil | 01/04/2007 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 31/12/1987 |
Formation de Mario Thomas
| Université Laval | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| 9342-8530 QUÉBEC INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Biochem Pharma, Inc.
 Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | Health Technology |
Terragen Discovery, Inc.
 Terragen Discovery, Inc. Pharmaceuticals: MajorHealth Technology Part of Cubist Pharmaceuticals LLC, Terragen Discovery, Inc. is a developer of antibiotics and patent drugs. The company is based in Vancouver, Canada. Terragen Discovery was acquired by Cubist Pharmaceuticals LLC on October 26, 2000 for $25.61 million. | Health Technology |
Biogentis, Inc.
Biogentis, Inc. Pharmaceuticals: MajorHealth Technology Biogentis, Inc. is a biopharmaceutical company, which designs and develops healthcare solutions in the field of advanced wound care and regenerative medicines. The company provides three technology platforms: Dermalink, a fibronectin-based product for chronic wound healing, CyanoStrip, a wound closure system and a self-assembly tissue engineering technology. It is located in Montréal, Canada | Health Technology |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
Aurelium BioPharma, Inc.
 Aurelium BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Aurelium BioPharma Inc., develops therapeutics and diagnostics for the treatment of drug-resistant cancers. The company has developed several diagnostic tests for the detection of breast, ovarian as well as drug-resistant cancers. The firm has a strong drugable pipeline of novel targets and complimentary diagnostic products that are utilized in its strategic collaborations and out-licensing efforts. The company was founded in May 1998 and is headquartered in Laval, Canada. | Health Technology |
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Health Technology |
Entomed SA
 Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
| Gestion T2C2/Bio, Inc. | |
Precision Biomonitoring, Inc.
Precision Biomonitoring, Inc. Medical/Nursing ServicesHealth Services Precision Biomonitoring, Inc. was founded in 2016 and specializes in providing SARS-CoV-2 test solutions for businesses. The private company is based in Guelph, Canada. The Canadian company's services include both mobile and laboratory RT-qPCR solutions. | Health Services |
